The Conversation (0)
Theratechnologies will share the results of its Phase IIb trial for TMB-202 at the IAS Conference on HIV Science.
Theratechnologies (TSX:TH) will share the results of its Phase IIb trial for TMB-202 at the IAS Conference on HIV Science.
As quoted in the press release:
Ibalizumab
The Phase II data for ibalizumab, a long-acting monoclonal antibody, show no significant difference in susceptibility (measured by maximum percent inhibition or ICHALFMAX Fold Change) in patient HIV isolates that were either sensitive or resistant to other antiretroviral agents, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, enfuvirtide and maraviroc.
“HIV drug resistance is a key topic at the IAS conference this year, and these findings are particularly important as they suggest that ibalizumab is equally active against HIV whether it is resistant or responsive to approved antiretroviral agents,” said Steve Weinheimer, Vice President, Biological Sciences at TaiMed Biologics USA. “On the heels of the BLA acceptance for priority review, these data provide additional support for ibalizumab as a potential tool for the treatment of multidrug resistant HIV-1,” added Mr. Weinheimer.
Click here to read the full press release.
Source: www.marketwired.com
